

Faculty Senate Meeting Minutes January 12, 2011

- I. Welcome: Meeting called to order at 4:30PM
- II. Minutes of December 14, 2010 meeting were approved.
- III. Dean's Comments - Dean Richard Krugman

A) Status of Searches:

- ii.) Surgery Chair Search, committee has been appointed, has not yet met.
- iii.) Emergency Medicine Chair Search now narrowed to 7 candidates, will be visiting over the coming 6-7 weeks and the hope is to have a new Chair by July 1, 2011.
- iv.) UPI Executive Director Search has been concluded. Jane Schumacher from Chicago has accepted to become Executive Director of UPI and Senior Associate Dean for Finance and Administration. Anticipated start date is March 1, 2011.
- v.) New search: Dean of School of Public Health. There is an interim Dean, Judith Albino and first search committee meeting will be on 01/14/2011.

B) Affiliation Agreements:

- ii.) Denver Health: in legal review.
- iii.) National Jewish Hospital: draft agreement work continues.
- iv.) VA Hospital agreement work continues.

The VA will occupy the former UPI building in February 2011 and plans to be moved to AMC in 2014.

IV. Discussion Items

A. Linda Crnic Institute Update: Presented by Edward McCabe, MD, Executive Director, Linda Crnic Institute for Down Syndrome.

The [Linda Crnic Institute for Down Syndrome](#) was founded in 2008. It is the first global institute for basic research, clinical research and clinical care specifically for people with Down syndrome. The mission of the institute is to eradicate the medical and cognitive ill effects associated with Down syndrome. Significantly improving the lives of people with Down syndrome is a major focus. The institute

partners are the University of Colorado Anschutz Medical Campus, the University of Colorado Boulder and The Children's Hospital.

More information on the Institute is available at:

<http://www.ucdenver.edu/academics/colleges/medicalschoo/institutes/lindacrn/Pages/lindacrn.aspx>.

Highlights:

- i.) Clinical services are provided at the Sie Center for Down Syndrome at The Children's Hospital. The goal of the Sie Center is to provide, locally and globally, the highest quality clinical care and therapeutic development to people with Down syndrome, hire and mentor a medical "dream team," provide up-to-date information on Down syndrome to parents who have received a prenatal diagnosis of Down syndrome and participate in collaborative ground-breaking clinical trials. The Sie Clinic opened on November 16, 2010.
- ii.) Basic Research is done at School of Medicine and UC Boulder.
- iii.) Clinical Research and Service done at The Children's Hospital.

Faculty appointments will be done in the departments and not in the LCI. Faculty categories are the core faculty, recruited by LCI and associate faculty with interest in Down Syndrome – to be identified by departments and encouraged to apply. Director of Research search is in progress and the Senior Research Scientist Boulder search will start in September 2011. The goal is to have 15 faculty members by 2015, 12 at Anschutz Medical Campus and 3 in Boulder.

B. Update Pro Publica: Presented by Dean Krugman.

Background – see previous minutes November 9, 2010 Faculty Senate Meeting. Also, additional details of presentation are available on the slide presentation attached to these minutes.

Over the past 2 months, the chairs of all the departments had conversations with the individual faculty members who were mentioned in the Denver Post Article. It became apparent that most of the payments were one time occurrences, a series of one time occurrences or were exempt activities. Of those faculty that were not in compliance with the current policy, most were not aware of the policy, misinterpreted or misunderstood them.

The Executive Committee met and recommended that there be:

- 1) A change in the policy and prohibit participation in activities that would be incompatible with COI of SOM, such as speakers' bureaus.

- 2) A change in the UPI Practice Agreement to report all professional compensations through UPI and to clearly limit the Exempt Honoraria list.

Risks to faculty and to SOM of not changing the policies were outlined, including but not limited to unintentional violations of the CU, SOM and UPI policies, faculty being subjected to restrictions imposed by industry, loss of public trust, inconsistent messages regarding importance of bioscience research and damage to SOM reputation.

Importance of change is emphasized because the publication so far is for a small amount of companies (7) and short amount of time (2 quarters), thus the likelihood of many more instances of violations is high. So far, there is no indication that there is a major issue with faculty disclosures on CU and SOM list, but there is not uniform concordance with UPI policy.

Possibilities to increase compliance include a “Site of Practice” type committee as was done in the past when TCH radiology department was disadvantaged in 1991 and/or instituting a mechanism for quick review of exceptions with temporary approval by chair of the committee and final approval at a monthly meeting. The possibility of submission of Form 1040 was also considered; at this time only on request of the chair and at annual review whenever questions arise.

Discussion and Questions Summary:

** There is confusion about what constitutes a speakers’ bureau and consulting. Nomenclatures of organizations can also change and make matters unclear, example: KOL = Key Opinion Leaders. Not all speakers’ bureau engagements are marketing and not all consulting is free of bias. Several senators believe that public will not care whether drug company compensation comes from one or the other.

** Will all honoraria be subject to Dean’s tax – is being debated.

** UPI proposed to be “bank and business” that will do collections. Any consulting should be processed through UPI so it is clear whether there is any marketing involved.

** Discussion about “FDA Approved Slides” – appears to be not a formal process of review and approval, but a mechanism to ensure that no off label recommendations are made. The problem is that if faculty uses their own slides, they would violate the contract signed with the drug company, which requires use of their slides in order to ensure FDA compliance.

** Emphasis that it is important for faculty to continue giving talks outside of own institution in order to:

- gain national recognition and meet requirement for promotion.
- bring grants to the institution.

** Look for a way to not rely on pharmaceutical company for CME and promotion opportunities.

** Possible consequences of not reporting the activities and income were discussed, also the possibility of an amnesty period for those who now know they are in violation and report before a certain deadline.

** Ideally, the new policy will be one that is simple, account for all income, and have a mechanism for transparency and quick adjudication. Faculty should be involved in determining the consequences of non-compliance. The goal is to form a body/committee to work on this and come up with guidelines. This way, faculty would have more buy-in and the policy will be more likely to be a success. The alternative, a handful of leaders setting up a policy, will have high likelihood of failure.

** Dean Krugman encourages all present to go back to their departments and discuss the topic, come back to this body and pass on any recommendations and feedback in the next month or two.

Meeting adjourned at 5:50PM

Debra A. Bislip, M.D., FAAFP
Faculty Senate Secretary